GSK126-GSK2816126A-DataSheet-生命科學(xué)試劑-MedChemExpress

1、Hotline: 400-820-3792Inhibitors Agonists Screening Librarieswww.MedChemEGSK126Cat. No.: HY-13470CAS No.: 1346574-57-9Synonyms: GSK2816126A分式: CHNO分量: 526.67作靶點: Histone Methyltransferase作通路: Epigenetics儲存式: Powder -20C 3 years4C 2 yearsIn solvent -80C 6 months-20C 1 month溶解性數(shù)據(jù)體外實驗 DMSO : 12.5 mg/mL

2、(23.73 mM; Need ultrasonic)H2O : 40% PEG300 5% Tween-80 45% salineSolubility: 1.25 mg/mL (2.37 mM); Clear solution2. 請依序添加每種溶劑： 10% DMSO 90% corn oilSolubility: 1.25 mg/mL (2.37 mM); Clear solution1/3 Master of Small Molecules 您邊的抑制劑師www.MedChemE3. 請依序添加每種溶劑： 20% SBE-CD adjusted to pH 4-4.5 with 1 N

3、 aceticSolubility: 20 mg/mL (37.97 mM); Clear solution; Need ultrasonic and warmingBIOLOGICAL ACTIVITY物活性 GSK126 (GSK2816126A)種有效，選擇性的 EZH2 甲基轉(zhuǎn)移酶抑制劑，IC50 為 9.9 nM。IC50 & Target EZH29.9 nM (IC50)體外研究 GSK126 potently inhibits both wild-type and mutant EZH2 methyltransferase activity with similar poten

4、cies(Ki=0.5-3 nM) independent of substrate used, and is competitive with S-adenosyl-methionine (SAM) and non-competitive with peptide substrates. GSK126 is highly selective against other methyltransferases andmultiple other protein classes (EZH1, IC50=680 nM) 1. Treatment of three SCLC cell lines wi

5、th GSK126,induces growth inhibition. SCLC cell lines (Lu130, H209, and DMS53) are treated with 0.5, 2, and 8 MGSK126, and growth curve is analyzed by WST-8 assay. Inhibition of cellular growth by GSK126 treatment isobserved at 8 M in all the three cell lines, while Lu130 and H209 are more sensitive

6、to GSK126, even atlower doses 2.體內(nèi)研究 GSK126 is administered intraperitoneally at a dose volume of 0.2 mL per 20 g body weight in female beigeSCID mice. GSK126 effectively inhibits the proliferation of EZH2 mutant DLBCL cell lines and markedlyinhibits the growth of EZH2 mutant DLBCL xenografts in mic

7、e 1.PROTOCOLKinase Assay 1 The five-member PRC2 complex (Flag-EZH2, EED, SUZ12, AEBP2, RbAp48) containing either wild-type ormutant (A677G, Y641N, Y641C, Y641H, Y641S or Y641F) EZH2 is prepared. GSK126 is dissolved in DMSOand tested at concentrations of 0.6 nM to 300 nM with a final DMSO concentrati

8、on of 2.5%. In contrast towild-type EZH2 which prefers H3K27me0 as a substrate in vitro, EZH2 Y641 mutants prefer H3K27me2 andhave little activity with H3K27me0 or H3K27me1. The A677G mutant is distinct from both the wild-type andY641 mutant forms of EZH2 in that it efficiently methylates H3K27me0,

9、H3K27me1, and H3K27me2;therefore, histone H3 peptides (residues 21-44; 10 M final) with either K27me0 (wild type, A677G EZH2),K27me1 (A677G EZH2), or K27me2 (A677G, Y641N, Y641C, Y641H, Y641S and Y641F EZH2) are used asmethyltransferase substrates. GSK126 is added to plates followed by addition of 6

10、 nM EZH2 complex andpeptide. As the potency of GSK126 is at or near the tight binding limit of an assay run at SAM=Km, IC50values are measured at a high concentration of the competitive substrate SAM relative to its Km (7.5 MSAM where the SAM Km is 0.3 M) 1.MCE has not independently confirmed the ac

11、curacy of these methods. They are for reference only.Cell Assay 2 JUB- and PTRF-introduced DMS53 cells are seeded at density of 1103 cells/well in 96-well plate, andcellular growth is analyzed using WST-8 kit at 12, 36, 60, and 84 h. Cellular growth of Lu130, H209, andDMS53 with treatment by DZNep o

12、r GSK126 is also analyzed using WST-8 kit. DZNep is dissolved in PBS at2/3 Master of Small Molecules 您邊的抑制劑師www.MedChemE5 mM, and cells are cultured at the final concentration of 5 M. GSK126 is dissolved in DMSO at 10 mM, andcells are cultured at 0.5, 2, and 8 M 2.MCE has not independently confirmed

13、 the accuracy of these methods. They are for reference only.Animal Mice 1Administration 1 GSK126 or vehicle is administered intraperitoneally at a dose volume of 0.2 mL per 20 g body weight. Pfeifferor KARPAS-422 cells (1107) in 100% Matrigel are implanted subcutaneously in female beige SCID mice.Tu

14、mors are measured with calipers, and block randomized according to tumour size into treatment groups.For efficacy studies, 10 mice are randomized in each treatment group before the initiation of dosing andGSK126 treatment is initiated once the tumour volumes are approximately 200 mm3 in the Pfeiffer

15、 andKARPAS-422 studies and 500 mm3 in the KARPAS-422 intermittent dosing study. Mice are weighed andtumors measured with calipers twice weekly. Two-tailed t-tests are conducted assuming two samples ofequal variance.MCE has not independently confirmed the accuracy of these methods. They are for refer

16、ence only.戶使本產(chǎn)品發(fā)表的科研獻 Cell. 2018 Sep 20;175(1):186-199.e19. J Exp Med. 2018 May 7;215(5):1365-1382. Cell Syst. 2018 Apr 25;6(4):424-443.e7. Cell Rep. 2018 Feb 27;22(9):2236-2245. Cell Death Dis. 2018 Jan 26;9(2):129.See more customer validations on HYPERLINK / www.MedChemEREFERENCES1. McCabe MT, et al. EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations. Nature. 2012 Dec6;492(7427):108-12.2. Sato T, et al. PRC2 overexpression and PRC2-target gene repression relating to poorer prognosis in